GMED Stock Chart & Stats
$1390.45
$0.00(0.00%)
At close: 4:00 PM EDT
$1390.45
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$1,000.00 - $1,916.40
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
$177.77B
Enterprise Value$10.37K
Total Cash (Recent Filing)$595.14M
Total Debt (Recent Filing)$111.19M
Price to Earnings (P/E)18.9
Beta0.22
Next Earnings
Nov 10, 2026EPS Estimate
20.28Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.97
Shares Outstanding111,831,820
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.58
Price to Sales (P/S)4.02
P/FCF Ratio20.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$1,740.80Price Target Upside25.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)84.51
Revenue Forecast (FY)$54.28B
Bulls Say, Bears Say
Bulls Say
Organic Spine And Trauma GrowthGrowth is broad across core spine, international markets, and trauma rather than concentrated in one product line. Continued procedural volume, surgeon recruitment, and product pull-through can support durable share gains and revenue expansion over the next several quarters.
Margin Expansion And Cash GenerationHigher operating margins alongside strong cash generation indicate improving earnings quality and operating leverage. This internally generated liquidity can fund product development, commercial investment, integration work, and shareholder returns while supporting resilience through business transitions.
Conservative Balance SheetVery low leverage gives Globus substantial financial flexibility compared with a more debt-dependent business. The strong capital structure reduces interest and refinancing exposure, allowing management to invest in innovation, acquisitions, and market expansion without excessive balance-sheet strain.
Bears Say
Enabling Technologies Revenue PressureThe move toward flexible capital models may support future unit adoption but reduces near-term cash sales and reported revenue. Until deployed systems generate stronger implant pull-through, this mix shift can weigh on growth visibility and make the segment's financial contribution less predictable.
Nevro Integration And Demand WeaknessNevro's declining sales and ongoing integration changes create execution risk within the broader portfolio. Product-development and commercial restructuring may delay stabilization, while weaker trial activity can limit revenue contribution and distract resources from the company's established growth businesses.
Profitability VolatilityThe recovery in profitability is encouraging, but the history of sharp year-to-year margin changes indicates earnings power is not yet fully consistent. Mix, pricing, cost, and integration effects could therefore limit the durability of current margins over the next several quarters.
Globus Medical News
GMED FAQ
What was Globus Medical’s price range in the past 12 months?
Globus Medical lowest stock price was $1000.00 and its highest was $1916.40 in the past 12 months.
What is Globus Medical’s market cap?
Globus Medical’s market cap is $177.77B.
When is Globus Medical’s upcoming earnings report date?
Globus Medical’s upcoming earnings report date is Nov 10, 2026 which is in 62 days.
How were Globus Medical’s earnings last quarter?
Globus Medical released its earnings results on Aug 06, 2026. The company reported $22.719 earnings per share for the quarter, beating the consensus estimate of $18.633 by $4.086.
Is Globus Medical overvalued?
According to Wall Street analysts Globus Medical’s price is currently Undervalued.
Does Globus Medical pay dividends?
Globus Medical does not currently pay dividends.
What is Globus Medical’s EPS estimate?
Globus Medical’s EPS estimate is 20.28.
How many shares outstanding does Globus Medical have?
Globus Medical has 111,831,820 shares outstanding.
What happened to Globus Medical’s price movement after its last earnings report?
Globus Medical reported an EPS of $22.719 in its last earnings report, beating expectations of $18.633. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Globus Medical?
Currently, no hedge funds are holding shares in MX:GMED
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Globus Medical Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,740.80 (25.20% Upside)
$1,740.80 (25.20% Upside)
Blogger Sentiment
Bullish
MX:GMED Sentiment 80%
Sector Average 60%
Sector Average 60%
Insider Transactions
Sold Shares
Worth $70.8M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
26.01%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
10.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Globus Medical
Globus Medical, Inc. is a global medical technology company dedicated to inventing, developing, and marketing a diverse range of healthcare solutions. Their primary focus is on addressing musculoskeletal disorders for patients worldwide. Their extensive portfolio includes a variety of spinal products. These encompass traditional fusion implants like pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices, all designed to treat conditions such as degenerative diseases, deformities, tumors, and trauma. Furthermore, they offer advanced motion preservation technologies, including dynamic stabilization, total disc replacement, and interspinous distraction devices. The company also provides interventional pain management options for vertebral compression fractures, alongside a selection of regenerative biologic products such as allografts and synthetic alternatives. Beyond spinal care, Globus Medical manufactures solutions for orthopedic trauma, featuring products like fracture plates, compression screws, intramedullary nails, and external fixation systems. They also specialize in hip and knee joint reconstruction, offering modular hip stems, acetabular cups, and various knee arthroplasty implants, including posterior stabilizing and cruciate retaining designs. Additionally, the company engages in the distribution of human cell, tissue, and other cellular and tissue-based products. Established in 2003, Globus Medical, Inc. maintains its corporate headquarters in Audubon, Pennsylvania.
GMED Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call was constructive: the company reported broad-based revenue growth (including strong U.S. and International Spine), meaningful margin expansion, record non-GAAP EPS, strong cash generation and continued product and commercial momentum. The main near-term headwinds are Enabling Technologies revenue compression due to a strategic shift to flexible capital models and a temporary top-line drag from the Nevro integration and trial cadence. Management provided reaffirmed revenue guidance and raised EPS guidance, signaling confidence in margin leverage and recovery of transitional businesses.View all MX:GMED earnings summariesGMED Net sales Breakdown
92.34% Musculoskeletal Solutions
7.66% Enabling Technologies
GMED Stock 12 Month Forecast
Average Price Target
$1,740.80
▲(25.20% Upside)